Drug-HPMA-HuIg conjugates effective against human solid cancer.
POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS(2004)
摘要
N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA)-bound doxorubicin conjugated with human Ig as a targeting moiety was used
for the first time in the setting of metastatic breast cancer (patients E. G., J. K., K. R. and K.H.) and angiosarcoma (patient
D. H) resistant to conventional cytotoxic chemotherapy. It was confirmed that Dox-PHPMA-Hulg conjugate is stable and doxorubicin
remains in the peripheral blood mostly in its polymer-bound form. In patients E. G., J. K., K.R. and K.H. more than 116 biochemical
and immunological parameters were tested in blood samples taken from the patients 24 h, 48 h, 72 h, 7 d, 14 d and 21, 28 and
eight weeks after the treatment. In the patient E. G., 15 parameters had pathological values before the treatment. During
the treatment, seven parameters dropped permanently or temporarily to a normal level and seven moved markedly towards the
physiological value. While the number of peripheral blood reticulocytes was significantly decreased after the treatment with
free doxorubicin, their number was stable or elevated after the treatment with Dox-PHPMA-Hulg conjugate. Increased absolute
number of CD16+56+ and CD4+ cells in the peripheral blood and activation of NK and LAX cells in a human patients support the data previously obtained
in experimental animals pointing to a dual role, i.e. the cytotoxic and immunomobilizing character of doxorubicin-PHPMA conjugates
containing a targeting immunoglobulin moiety.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要